Bojang, Kalifa <br/><br/>
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.  [electronic resource] 

 -  Human vaccines  Apr 2009 
 - 242-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1554-8619 
<br/><br/><label>Standard No.: </label>10.4161/hv.5.4.7050  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Animals<br/>Antibodies, Protozoan--blood<br/>Antigens, Protozoan--immunology<br/>Endemic Diseases--prevention & control<br/>Follow-Up Studies<br/>Gambia--epidemiology<br/>Humans<br/>Malaria Vaccines--adverse effects<br/>Malaria, Falciparum--epidemiology<br/>Male<br/>Middle Aged<br/>Plasmodium falciparum--immunology<br/>Rabies Vaccines--adverse effects<br/>Young Adult